Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

search and development.

For more information, please visit http://us.boehringer-ingelheim.com

References

  1. Li D et al. "BIBW2992, an irreversible EGFR/HER2 inhibitor highlyeffective in preclinical lung cancer models." Oncogene 2008;27:4702-4711
  2. Shih J-Y et al. "A Phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of 1 line of chemotherapy (LUX-Lung 2)." Poster Discussion Presentation. 1 June 2009, Session Time: 8:00AM - 12:00PM. #8013
  3. "Ask the Expert Online Q&A: Are the number of cancer cases increasing or decreasing in the world?" 1 April 2008. World Health Organization. 5 May 2009. http://www.who.int/features/qa/15/en/print.html.
  4. Boehringer Ingelheim Pharmaceuticals. "BIBW 2992 and BSC Versus Placebo and BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)" 23 April 2009. ClinicalTrials.gov. 5 May 2009. http://clinicaltrials.gov/ct2/show/NCT00656136?term=BIBW+2992+and+Phase+III&rank=1.
  5. Yang C-H et al. "Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherap
    '/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... MADRID , October 30, 2014 ... build tolerance for cow milk   Cow milk protein allergy ... infants and early childhood. Until now, it has been ... Recently, it has been shown that it is possible ... in a significant number of children during the first ...
(Date:10/30/2014)... , Oct. 29, 2014 The ... basis of test type, technology, product, and geography. ... the highest growth rate in the newborn screening ... high growth is attributed to various nations opting ... a fundamental instrument used for expanded newborn screening. ...
(Date:10/30/2014)... 2014 Hospital stretchers are apparatus used ... another, inside or outside of medical infrastructure premises. ... also used for several specialized functions such as ... platforms. The hospital stretchers market report ... market potential of hospital stretchers globally. The hospital ...
Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter , ... to men with prostate cancer who also have certain heart ... cause, a new study suggests. , , The therapy in question ... cancer to reduce levels of male hormones to prevent the ... the current research, this hormone therapy was linked to triple ...
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 The annual ... (NAMS) came to a close on Saturday, October 18th, ... the Society’s inception in 1989. NAMS is North America’s ... quality of life of all women during midlife and ... With over 2,000 physicians and thought leaders from fields ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. ... chemical during pregnancy may have effects on genital development in ... baby boys born to moms with greater exposure to a ... -- the space between the genitals and anus. Anogenital distance ... of exposure to androgens ("male" hormones) during pregnancy. The ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- A new vaccine that ... disease was approved by the U.S. Food and Drug ... people between the ages of 10 and 25 from ... serogroup B bacteria. The bacteria can infect the ... cord and brain. It is a leading cause of ...
Breaking Medicine News(10 mins):Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... SOMERSET, N.J., Jan. 9 TeamStaff, Inc.,(Nasdaq: ... administrative,staffing services, today announced that on January 4, ... Nasdaq Stock Market ("Nasdaq"),indicating that TeamStaff,s common stock ... The Nasdaq,s determination was based on its July ...
... combat mortality , , WEDNESDAY, Jan. 9 (HealthDay News) -- ... question the conventional wisdom of treating with corticosteroids, intensive ... called pentastarch. , The first study compared the ... septic shock and found no improvement in survival rates. ...
... made that New Years resolution to exercise more, but already youre ... You know all the benefits of a healthy lifestyle: In addition ... been linked to reduced depressive symptoms and reduced risk for heart ... TV instead of going for a short jog is just too ...
... ROUGE, La., Jan. 9 The 11th annual ... Forum,entitled "Eliminating Disparities and Improving Access to,Relationship-Centered Care," ... Inn,Select, 4728 Constitution Avenue, Baton Rouge, La., from ... is redesigning patient-care delivery and improving access to,its ...
... Group Inc.,(Nasdaq: GSIG ), a leading manufacturer of ... be presenting at both the,Needham & Company 10th Annual ... the Fifth Annual Sidoti & Company Emerging Growth Conference ... Bowen, Chief Financial Officer, will be speaking at both,events., ...
... Americans increasingly seek a quick fix to physical and ... of a debate about the potential benefits and drawbacks ... panel discussion entitled, The Uses of Medications in Psychoanalysis: ... by internationally renowned psychoanalyst Glen O. Gabbard, M.D., at ...
Cached Medicine News:Health News:TeamStaff Receives Nasdaq Determination Letter 2Health News:TeamStaff Receives Nasdaq Determination Letter 3Health News:Standard Septic Shock Treatments Ineffective 2Health News:Standard Septic Shock Treatments Ineffective 3Health News:Standard Septic Shock Treatments Ineffective 4Health News:Exercising judgment: The psychology of fitness 2Health News:Exercising judgment: The psychology of fitness 3Health News:Exercising judgment: The psychology of fitness 4Health News:Exercising judgment: The psychology of fitness 5Health News:Exercising judgment: The psychology of fitness 6Health News:Exercising judgment: The psychology of fitness 7Health News:Exercising judgment: The psychology of fitness 8Health News:Exercising judgment: The psychology of fitness 9Health News:Exercising judgment: The psychology of fitness 10Health News:LSU Forum Examines Health-Care Disparities and Access to Care 2Health News:GSI to Present at Upcoming Investor Growth Conferences 2Health News:Uses of medications in psychoanalysis 2
Designed to give maximum drying area while taking up minimal bench space....
Used to remove wrinkles from sections and for reorientating embedded tissue....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: